Anahita Rouzé1,2,3, Séverine Loridant1,2,4, Julien Poissy1,2,3, Benoit Dervaux5,6, Boualem Sendid1,2,4, Marjorie Cornu1,2,4, Saad Nseir7,8,9. 1. U995-LIRIC-Lille Inflammation Research International Center, Univ. Lille, 59000, Lille, France. 2. U995, Inserm, 59000, Lille, France. 3. Critical Care Center, CHU Lille, 59000, Lille, France. 4. Laboratory of Mycology and Parasitology, CHU Lille, 59000, Lille, France. 5. UMR 8179, CNRS, 59000, Lille, France. 6. Public Health and Epidemiology Department, CHU Lille, 59000, Lille, France. 7. U995-LIRIC-Lille Inflammation Research International Center, Univ. Lille, 59000, Lille, France. s-nseir@chru-lille.fr. 8. U995, Inserm, 59000, Lille, France. s-nseir@chru-lille.fr. 9. Critical Care Center, CHU Lille, 59000, Lille, France. s-nseir@chru-lille.fr.
Abstract
PURPOSE: The aim of this study was to determine the impact of a biomarker-based strategy on early discontinuation of empirical antifungal treatment. METHODS: Prospective randomized controlled single-center unblinded study, performed in a mixed ICU. A total of 110 patients were randomly assigned to a strategy in which empirical antifungal treatment duration was determined by (1,3)-β-D-glucan, mannan, and anti-mannan serum assays, performed on day 0 and day 4; or to a routine care strategy, based on international guidelines, which recommend 14 days of treatment. In the biomarker group, early stop recommendation was determined using an algorithm based on the results of biomarkers. The primary outcome was the percentage of survivors discontinuing empirical antifungal treatment early, defined as a discontinuation strictly before day 7. RESULTS: A total of 109 patients were analyzed (one patient withdraw consent). Empirical antifungal treatment was discontinued early in 29 out of 54 patients in the biomarker strategy group, compared with one patient out of 55 in the routine strategy group [54% vs 2%, p < 0.001, OR (95% CI) 62.6 (8.1-486)]. Total duration of antifungal treatment was significantly shorter in the biomarker strategy compared with routine strategy [median (IQR) 6 (4-13) vs 13 (12-14) days, p < 0.0001). No significant difference was found in the percentage of patients with subsequent proven invasive Candida infection, mechanical ventilation-free days, length of ICU stay, cost, and ICU mortality between the two study groups. CONCLUSIONS: The use of a biomarker-based strategy increased the percentage of early discontinuation of empirical antifungal treatment among critically ill patients with suspected invasive Candida infection. These results confirm previous findings suggesting that early discontinuation of empirical antifungal treatment had no negative impact on outcome. However, further studies are needed to confirm the safety of this strategy. This trial was registered at ClinicalTrials.gov, NCT02154178.
RCT Entities:
PURPOSE: The aim of this study was to determine the impact of a biomarker-based strategy on early discontinuation of empirical antifungal treatment. METHODS: Prospective randomized controlled single-center unblinded study, performed in a mixed ICU. A total of 110 patients were randomly assigned to a strategy in which empirical antifungal treatment duration was determined by (1,3)-β-D-glucan, mannan, and anti-mannan serum assays, performed on day 0 and day 4; or to a routine care strategy, based on international guidelines, which recommend 14 days of treatment. In the biomarker group, early stop recommendation was determined using an algorithm based on the results of biomarkers. The primary outcome was the percentage of survivors discontinuing empirical antifungal treatment early, defined as a discontinuation strictly before day 7. RESULTS: A total of 109 patients were analyzed (one patient withdraw consent). Empirical antifungal treatment was discontinued early in 29 out of 54 patients in the biomarker strategy group, compared with one patient out of 55 in the routine strategy group [54% vs 2%, p < 0.001, OR (95% CI) 62.6 (8.1-486)]. Total duration of antifungal treatment was significantly shorter in the biomarker strategy compared with routine strategy [median (IQR) 6 (4-13) vs 13 (12-14) days, p < 0.0001). No significant difference was found in the percentage of patients with subsequent proven invasive Candida infection, mechanical ventilation-free days, length of ICU stay, cost, and ICU mortality between the two study groups. CONCLUSIONS: The use of a biomarker-based strategy increased the percentage of early discontinuation of empirical antifungal treatment among critically illpatients with suspected invasive Candida infection. These results confirm previous findings suggesting that early discontinuation of empirical antifungal treatment had no negative impact on outcome. However, further studies are needed to confirm the safety of this strategy. This trial was registered at ClinicalTrials.gov, NCT02154178.
Authors: O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann Journal: Clin Microbiol Infect Date: 2012-12 Impact factor: 8.067
Authors: Brunella Posteraro; Mario Tumbarello; Gennaro De Pascale; Elvira Liberto; Maria S Vallecoccia; Elena De Carolis; Valentina Di Gravio; Enrico M Trecarichi; Maurizio Sanguinetti; Massimo Antonelli Journal: J Antimicrob Chemother Date: 2016-04-28 Impact factor: 5.790
Authors: Olivier Leroy; Jean-Pierre Gangneux; Philippe Montravers; Jean-Paul Mira; François Gouin; Jean-Pierre Sollet; Jean Carlet; Jacques Reynes; Michel Rosenheim; Bernard Regnier; Olivier Lortholary Journal: Crit Care Med Date: 2009-05 Impact factor: 7.598
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Maiken C Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William W Hope Journal: Drug Resist Updat Date: 2014-01-27 Impact factor: 18.500
Authors: Ignacio Martin-Loeches; Massimo Antonelli; Manuel Cuenca-Estrella; George Dimopoulos; Sharon Einav; Jan J De Waele; Jose Garnacho-Montero; Souha S Kanj; Flavia R Machado; Philippe Montravers; Yasser Sakr; Maurizio Sanguinetti; Jean-Francois Timsit; Matteo Bassetti Journal: Intensive Care Med Date: 2019-03-25 Impact factor: 17.440
Authors: E Bouza; B Almirante; J García Rodríguez; J Garnacho-Montero; M Salavert; P Muñoz; M Sanguinetti Journal: Rev Esp Quimioter Date: 2019-11-14 Impact factor: 1.553
Authors: Gennaro De Pascale; Brunella Posteraro; Sonia D'Arrigo; Giorgia Spinazzola; Rita Gaspari; Giuseppe Bello; Luca Maria Montini; Salvatore Lucio Cutuli; Domenico Luca Grieco; Valentina Di Gravio; Giulia De Angelis; Riccardo Torelli; Elena De Carolis; Mario Tumbarello; Maurizio Sanguinetti; Massimo Antonelli Journal: Crit Care Date: 2020-09-05 Impact factor: 9.097